Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 8569 - 8576 of 12086 results
Immigration Considerations for a Start-Up Company
February 24, 2016| Article| Viewpoint
Opioids, FDA and Medicare Advantage Spending on the List for Congress
February 24, 2016| Blog| Viewpoint
Innocents Abroad: Employer Considerations When Sending Employees on International Assignments or Business Travel
February 24, 2016| Blog| Viewpoint
The Life Sciences Lease: A Marathon, Not a Sprint
February 24, 2016| Blog| Viewpoint
Monkey See, Monkey Sue Doesn’t Fly Under U.S. Copyright Law
February 24, 2016| Blog| Viewpoint
CPSC Adopts Mohorovic’s $250 Million Burden Relief Proposal for Adult Apparel
February 24, 2016| Blog| Viewpoint
Congress to Continue Work on Energy Issues Amid Supreme Court Uncertainty
February 23, 2016| Blog| Viewpoint
Groundbreaking Multi-Payer Alignment on Core Measures for Quality-Based Payments
February 23, 2016| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|